|
|
|
|
Peroxisome proliferator-activated receptor-alpha (PPAR-alpha): At the crossroads of obesity, diabetes and card
PPAR-alpha has central co-ordinated role in regulation of fatty acid oxidation, lipid and lipoprotein metabolism, inflammatory and vascular responses, all predicted to reduce atherosclerotic risk Fenofibrate Intervention and Event...
|
|
|
Cholesterol Drug Cuts Amputation Risk in Diabetes
Treating Type 2 diabetes patients with a cholesterol-lowering drug called fenofibrate cuts the risk of a first diabetes-related limb amputation by 36%, according to a new study published in The Lancet.James Best, MD, professor of medicine...
|
|
|
Fenofibrate use linked with fewer amputations in type 2 diabetes
Use of fenofibrate can lower the risk of some types of amputation in people with type 2 diabetes, according to a prespecified subanalysis of a 9,795-patient study, published recently in The Lancet (2009;373:1780).The analysis showed that,...
|
|
|
Effect of Fenofibrate on Amputation Events in People With Type 2 Diabetes Mellitus (FIELD Study): A Prespecifi
Fenofibrate treatment may lower the risk of amputations for patients with type 2 diabetes, particularly minor amputations without a known large-vessel disease, new research suggests.The Fenofibrate Intervention and Event...
|
|
|
Fenofibrate decreased amputation risk in type 2 diabetes
Patients with type 2 diabetes had a 36% lower risk for first-time amputations particularly below the ankle when assigned to long-term treatment with fenofibrate compared with patients assigned to placebo, according to data from the FIELD...
|
|
|
Fenofibrate reduces risk for microvascular disease related amputation
MedWire News: Treatment of patients with Type 2 diabetes without known large-vessel disease with fenofibrate significantly reduces their risk for amputation events, report researchers from the FIELD study.However, the risk for major...
|
|
|
Fenofibrate may reduce amputations in diabetics
NEW YORK (Reuters Health) - Treatment with fenofibrate can reduce the risk of amputation in people with type 2 diabetes by 36%, according to a report in the May 23rd issue of The Lancet.The effect, which is probably mediated through non...
|
|
|
Fenofibrate-induced HDL effect may be influenced by homocysteine increase
MedWire News: Results from the FIELD study show that patients with greater fenofibrate-mediated increases in homocysteine are likely to have smaller increases in high-density lipoprotein (HDL) cholesterol, perhaps explaining the variable...
|
|
|
Aussie, N.Z. Study Finds Fenofibrate Lowers Diabetes Amputation Risk
If you are an individual print subscriber to an FDC Reports publication and have Aussie, N.Z.Study Finds Fenofibrate Lowers Diabetes Amputation Risk.
|
|
|
Fenofibrate May Lower Risk for First Type 2 Diabetes-Related Amputation
_ Fenofibrate May Lower Risk for First Type 2 Diabetes-Related Amputation.
|
|
|
Fenofibrate May Lower Risk for First Type 2 Diabetes-Related Amputation
_ Fenofibrate May Lower Risk for First Type 2 Diabetes-Related Amputation.
|
|
|
Fenofibrate May Lower Risk for First Type 2 Diabetes-Related Amputation
_ Fenofibrate May Lower Risk for First Type 2 Diabetes-Related Amputation.
|
|
|
Drug Cuts Amputation Risk in Diabetes
-- Treating patients with a cholesterol-lowering drug called fenofibrate cuts the risk of a first diabetes-related limb amputation by 36%, according to a new study published this week in The Lancet.'I would call that a substantial...
|
|
|
Notice of Cipher Pharmaceuticals Inc. fiscal 2009 first quarterconference call
- Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 7 /CNW/ - Cipher Pharmaceuticals Inc.(TSX: DND), will host a conference call on Wednesday, May 13, 2009 at 8:30 a.m. (ET) to discuss its fiscal 2009 first quarter financial...
|
